Cognition Therapeutics (NASDAQ:CGTX) CFO John Brendan Doyle Acquires 10,000 Shares

Cognition Therapeutics, Inc. (NASDAQ:CGTX) CFO John Brendan Doyle bought 10,000 shares of the company’s stock in a transaction dated Thursday, April 16th. The stock was bought at an average cost of $1.13 per share, with a total value of $11,300.00. Following the acquisition, the chief financial officer directly owned 627,509 shares of the company’s stock, valued at approximately $709,085.17. The trade was a 1.62% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Cognition Therapeutics Stock Performance

Shares of CGTX traded down $0.07 during mid-day trading on Monday, reaching $1.12. The company had a trading volume of 1,002,761 shares, compared to its average volume of 1,047,733. The company has a market capitalization of $100.07 million, a price-to-earnings ratio of -3.39 and a beta of 1.39. The company’s 50 day simple moving average is $1.03 and its 200 day simple moving average is $1.36. Cognition Therapeutics, Inc. has a 1-year low of $0.22 and a 1-year high of $3.83.

Cognition Therapeutics (NASDAQ:CGTX) last released its quarterly earnings data on Thursday, March 26th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.04. As a group, equities analysts forecast that Cognition Therapeutics, Inc. will post -0.31 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on CGTX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cognition Therapeutics in a report on Friday, March 27th. Chardan Capital restated a “buy” rating and set a $4.00 price objective on shares of Cognition Therapeutics in a research report on Friday, March 27th. Finally, raised Cognition Therapeutics to a “strong-buy” rating in a report on Tuesday, February 3rd. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $3.33.

Institutional Investors Weigh In On Cognition Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Acadian Asset Management LLC increased its position in Cognition Therapeutics by 814.1% in the 1st quarter. Acadian Asset Management LLC now owns 1,007,586 shares of the company’s stock valued at $422,000 after acquiring an additional 897,353 shares during the period. DAVENPORT & Co LLC acquired a new position in shares of Cognition Therapeutics during the third quarter worth $3,631,000. CWA Asset Management Group LLC acquired a new position in shares of Cognition Therapeutics during the third quarter worth $34,000. McAdam LLC bought a new stake in shares of Cognition Therapeutics in the third quarter worth $97,000. Finally, Bryn Mawr Trust Advisors LLC increased its holdings in Cognition Therapeutics by 69.1% in the third quarter. Bryn Mawr Trust Advisors LLC now owns 39,466 shares of the company’s stock valued at $53,000 after purchasing an additional 16,129 shares during the period. 43.35% of the stock is owned by institutional investors.

About Cognition Therapeutics

Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer’s disease. The company’s lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer’s disease.

CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer’s disease.